DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: A Systematic Review and Meta-Analysis

Malignant mesothelioma is an aggressive cancer type linked to asbestos exposure. Because of several intrinsic challenges, often diagnosed in advanced disease stage. Therefore, there a need for diagnostic biomarkers that may contribute early detection. Recently, the epigenome tumors being extensively investigated identify biomarkers. This manuscript systematic review summarizing state-of-the-art research investigating DNA methylation mesothelioma. Four literature databases (PubMed, Scopus, Web Science, MEDLINE) were systematically searched studies up October 16, 2020. A meta-analysis was performed per gene at least two independent studies. total 53 97 genes and are described qualitative overview. Furthermore, ten 13 (APC, CDH1, CDKN2A, DAPK, ESR1, MGMT, miR-34b/c, PGR, RAR?, RASSF1, SFRP1, SFRP4, WIF1) included quantitative meta-analysis. In this meta-analysis, APC significantly hypomethylated mesothelioma, whereas WIF1 hypermethylated The three most appropriate candidate from APC, WIF1. Nevertheless, both study number objects comprised too low draw final conclusions on their clinical applications. elucidation genome-wide profile desirable future, using standardized analysis approach. informative CpG sites signature could then form basis panel highly sensitive specific can be used diagnosis even screening high-risk population asbestos-exposed individuals.